Midnight Health, L'Oréal partner for acne trial

Midnight Health, an emerging leader in telehealth solutions, has formed a strategic partnership with L’Oréal Dermatological Beauty brands of the L’Oréal Groupe.

This collaboration initiates an observational study targeting mild to moderate acne, set to run from March to May 2024. The trial will incorporate La Roche Posay’s specialised skincare products with Midnight Health’s clinical team, technology and consumer platform: hub.health.

“At L’Oréal Dermatological Beauty, we are excited to forge this new partnership with Midnight Health, one of our first within the telehealth space, where innovation meets care. Together, we can bridge the gap between distance and access, combining Midnight Health’s healthcare expertise and our passion for skincare solutions directly to the fingertips of patients,” said Samantha Russell — Medical Director, L’Oréal Dermatological Beauty.

Acne affects up to 93.3% of teenagers in Australia, carrying significant psychological and social impact that can severely affect quality of life. Acne not only imposes a high cost on patients and the community through prolonged treatment courses and lower employment rates, but also affects school and work performance. With GPs in Australia recording acne as a concern in 0.4 of every 100 consultations¹, the study is of particular relevance to general practice, the companies said in a joint statement.

By combining L’Oréal Dermatological Beauty’s skincare solutions with Midnight Health’s telehealth technology, this study — with limited enrolment — aims to offer new insights into acne treatments. Participants will receive the latest skincare advances with the benefits of telehealth support and treatments delivered to their door.

^{1 RACGP - Acne in primary care}

Image credit: iStock.com/Yuliya